Endostatin, an antiangiogenic protein, is expressed in the unilateral ureteral obstruction mice model

Journal of Nephrology

Volumn 21, Issue 5, 2008, Pages 753-760

  Maciel, Thiago T ^a   Coutinho, Enia L ^a   Soares, Debora ^a   Achar, Eduardo ^a   Schor, Nestor ^a   Bellini, Maria H ^a,b  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO DE PESQUISAS ENERGÉTICAS E NUCLEARES   (Brazil)

Author keywords

Endostatin; Proximal tubular cells; Tubulointerstitial fibrosis; Unilateral ureteral obstruction

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD31 ANTIGEN; COLLAGEN TYPE 18; ENDOSTATIN; MESSENGER RNA; TRANSFORMING GROWTH FACTOR BETA1; ANGIOGENESIS INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; COLLAGEN SYNTHESIS; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; MOUSE; NONHUMAN; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; URETER OBSTRUCTION; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CELL LINE; KIDNEY; MALE; METABOLISM; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTIGENS, CD31; CELL LINE; COLLAGEN TYPE XVIII; ENDOSTATINS; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MICE; MICE, INBRED C57BL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFORMING GROWTH FACTOR BETA1; URETERAL OBSTRUCTION;

EID: 62949222910     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Nath KA. Tubulointerstitial changes as a major determinant in the progression of renal damage. Am J Kidney Dis. 1992;20:1-17.
2. Klahr S, Schreiner G, Ichikawa I. The progression of renal disease. N Engl J Med. 1988;318:1657-1666.
3. Sharma AK, Mauer SM, Kim Y, Michael AF. Interstitial fibrosis in obstructive nephropathy. Kidney Int. 1993;44:774-788.
4. Klahr S, Morrissey J. Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol. 2002;283:F861-F875.
5. Eckardt KU, Bernhardt WM, Weidemann A, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl. 2005;68:S46-S51.
6. Nangaku M. Hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. Nephron Exp Nephrol. 2004;98:e8-e12.
7. Higgins DF, Biju MP, Akai Y, Wutz A, Johnson RS, Haase VH. Hypoxic induction of Ctgf is directly mediated by Hif-1. Am J Physiol Renal Physiol. 2004;287:F1223-F1232.
8. Li X, Kimura H, Hirota K, et al. Synergistic effect of hypoxia and TNF-alpha on production of PAI-1 in human proximal renal tubular cells. Kidney Int. 2005;68:569-583.
9. Zhang B, Liang X, Shi W, et al. Role of impaired peritubular capillary and hypoxia in progressive interstitial fibrosis after 56 subtotal nephrectomy of rats. Nephrology (Carlton). 2005;10:351-357.
10. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277-285.
11. O'Riordan E, Mendelev N, Patschan S, et al. Chronic NOS inhibition actuates endothelial-mesenchymal transformation. Am J Physiol Heart Circ Physiol. 2007;292:H285-H294.
12. Morrissey J, Klahr S. Transcription factor NF-kappaB regulation of renal fibrosis during ureteral obstruction. Semin Nephrol. 1998;18:603-611.
13. Ohashi R, Shimizu A, Masuda Y, et al. Peritubular capillary regression during the progression of experimental obstructive nephropathy. J Am Soc Nephrol. 2002;13:1795-1805.
14. Hajitou A, Grignet C, Devy L, et al. The antitumoral effect of endostatin and angiostatin is associated with a down-regulation of vascular endothelial growth factor expression in tumor cells. FASEB J. 2002;16:1802-1804.
15. Kim YM, Hwang S, Pyun BJ, et al. Endostatin blocks vascular endothelial growth factor-mediated signaling via direct interaction with KDR/Flk-1. J Biol Chem. 2002;277:27872-27879.
16. Delaney CE, Weagant BT, Addison CL. The inhibitory effects of endostatin on endothelial cells are modulated by extracellular matrix. Exp Cell Res. 2006;312:2476-2489.
17. Chevalier RL, Thornhill BA, Wolstenholme JT. Renal cellular response to ureteral obstruction: role of maturation and angiotensin II. Am J Physiol. 1999;277:F41-F47.
18. Epstein FH, Agmon Y, Brezis M. Physiology of renal hypoxia. Ann N Y Acad Sci. 1994;718:72-81. Discussion 81-72.
19. Fine LG, Bandyopadhay D, Norman JT. Is there a common mechanism for the progression of different types of renal diseases other than proteinuria? Towards the unifying theme of chronic hypoxia. Kidney Int Suppl. 2000;75:S22-S26.
20. Bellini MH, Coutinho EL, Filgueiras TC, Maciel TT, Schor N. Endostatin expression in the murine model of ischaemia/reperfusion-induced acute renal failure. Nephrology (Carlton). 2007;12:459-465.
21. Ichinose K, Maeshima Y, Yamamoto Y, et al. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model. Diabetes. 2005;54:2891-2903.
22. Tanabe K, Maeshima Y, Ichinose K, et al. Endostatin peptide, an inhibitor of angiogenesis, prevents the progression of peritoneal sclerosis in a mouse experimental model. Kidney Int. 2007;71:227-238.
23. Sumi M, Satoh H, Kagohashi K, Ishikawa H, Sekizawa K. Increased serum levels of endostatin in patients with idiopathic pulmonary fibrosis. J Clin Lab Anal. 2005;19:146-149.